APRE
NASD Aprea Therapeutics, Inc.$0.6950 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.6950
- YTD change
- -18.52%
- vs 20-day SMA
- -8.76%
- vs 200-day SMA
- -11.83%
Price ranges
Price & Performance
-0.00 (-0.60%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.9% away from all-time highs of $1,062.2000
- APRE is down 19% since the beginning of the year
- APRE is down 54% over the past 12 months
- APRE is down 14% over the past 1 month
- 1% of all APRE investors are betting against APRE
APRE reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -53.2%.
- Previous minute
- +$0.0000
- Last hour
- +$0.0340
- Last 5 days
- -8.65%
- vs 8-day SMA
- -7.49%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
